Impact of Proposed Medicare Policy Changes for Botulinum Toxin Coverage on Hemifacial Spasm and Facial Dystonia

CLINICAL QUESTION

How might proposed Medicare coverage restrictions on botulinum toxin injections affect patients with hemifacial spasm, facial dystonia, and nonflaccid facial paralysis?

BOTTOM LINE

The proposed Medicare policy could restrict individualized botulinum toxin treatment by limiting reimbursable injection sites and initial dosing. The authors argue that these restrictions may result in undertreatment, persistent functional and psychosocial symptoms, medication waste, and potentially greater healthcare utilization.

BACKGROUND: Hemifacial spasm and facial dystonia cause involuntary facial movements that may impair speech, eating, vision, comfort, emotional expression, and social interaction. Botulinum toxin is a principal treatment because it reduces abnormal muscle activity, improves facial symmetry, and may lessen associated anxiety, depression, and quality-of-life impairment.

STUDY DESIGN: Viewpoint article examining a proposed Medicare Local Coverage Determination for botulinum toxin injections and discussing its potential clinical, ethical, and economic implications. The authors contextualized the proposed restrictions using published evidence on botulinum toxin dosing and outcomes in facial movement disorders.

SETTING: Facial plastic and reconstructive surgery practice and Medicare coverage policy in the U.S.

SYNOPSIS: The article evaluates CGS Administrators’ proposed Local Coverage Determination for botulinum toxin injections, which would reimburse only one injection per defined site regardless of the number of injection points used. The proposal also describes an initial total dose of 25-30 botulinum toxin units across selected muscles on the affected side of the face—including the orbicularis oculi, procerus, mentalis, platysma, orbicularis oris, and depressor anguli oris—with an additional 5-15 units potentially allowed after one year. The authors contend that these limits do not reflect the variability and complexity of facial movement disorders. Published dosing ranges cited in the article extend from 7.5-90 units for hemifacial spasm to 4-220 units across facial muscles for facial dystonia. Effective treatment may require several injection points within one muscle and treatment of both affected and contralateral compensatory muscles to optimize symmetry and function. The policy may also affect patients with nonflaccid facial paralysis, although this population is not clearly addressed. Botulinum toxin doses reported for these patients range from 2-106 units, and treatment may improve synkinesis, facial function, symmetry, psychological symptoms, and quality of life.

The authors warn that insufficient dosing could leave patients with residual spasms, pain, visual or oral functional limitations, and psychosocial distress. Lower dose limits might also increase follow-up visits and healthcare use while creating waste, because botulinum toxin is commonly supplied in single-use 50- or 100-unit vials. Finally, the authors call for policy revision in collaboration with facial nerve specialists and other stakeholders.

CITATION: Barna AJ, et al. Impact of proposed Medicare policy changes for botulinum toxin coverage on hemifacial spasm and facial dystonia. Facial Plast Surg Aesthet Med. 2025;27:513-515. doi:10.1089/fpsam.2024.0281.

COMMENT: Proposed Medicare coverage changes for botulinum toxin in treating hemifacial spasm, facial dystonia, and synkinesis would significantly impair clinicians’ abilities to treat these patients. This chemodenervation treatment is evidence based, and the proposed changes ignore this evidence. Barna et al. nicely summarize the proposed changes and negative impacts they would have on patient care. –Matthew Q. Miller, MD